# To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg

> **NCT00912145** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 26 (actual)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)

## Key facts

- **NCT ID:** NCT00912145
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-02
- **Primary completion:** 1996-02
- **Final completion:** 1996-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912145, "To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00912145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*